IFG Advisory’s Inovio Pharmaceuticals INO Stock Holding History

IFG Advisory’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-833	Closed	-$5.1K	–	473
2023 Q4	$5.1K	Hold	833	–	–	﹤0.01%	576
2023 Q3	$3.89K	Hold	833	–	–	﹤0.01%	537
2023 Q2	$4.46K	Hold	833	–	–	﹤0.01%	323
2023 Q1	$8.2K	Sell	833 -137	-14%	-$2.33K	﹤0.01%	509
2022 Q4	$18K	Hold	970	–	–	﹤0.01%	486
2022 Q3	$20K	Hold	970	–	–	﹤0.01%	512
2022 Q2	$20K	Hold	970	–	–	﹤0.01%	458
2022 Q1	$41K	Buy	970 +87	+10%	+$3.92K	﹤0.01%	486
2021 Q4	$52K	Hold	883	–	–	0.01%	494
2021 Q3	$75K	Hold	883	–	–	0.01%	476
2021 Q2	$98K	Buy	+883	New	+$84.8K	0.01%	467
2020 Q3	–	Sell	-9,770	Closed	-$3.16M	–	413
2020 Q2	$3.16M	Buy	9,770 +4	+0%	+$642	0.57%	41
2020 Q1	$871K	Buy	+9,766	New	+$602K	0.19%	126

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

IFG Advisory's INO Position: Q1 2024 in Review

IFG Advisory sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 833 shares — an estimated $5.1K sold.

IFG Advisory first reported a position in INO in Q1 2020 and held it in 13 quarters. The position peaked at $3.16M in Q2 2020. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

IFG Advisory reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
IFG Advisory sold 833 Inovio Pharmaceuticals shares in Q1 2024, an estimated $5.1K.
IFG Advisory first reported a position in Inovio Pharmaceuticals in Q1 2020 and held it in 13 quarters.
IFG Advisory's Inovio Pharmaceuticals position peaked at $3.16M in Q2 2020.
89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on IFG Advisory's 13F filing for Q1 2024, filed 6 May 2024.